{"abstract": "The industry\u2019s lobbying effort could blunt new competition to its products and reduce the savings anticipated in the federal health care overhaul.", "web_url": "https://www.nytimes.com/2013/01/29/business/battle-in-states-on-generic-copies-of-biotech-drugs.html", "snippet": "The industry\u2019s lobbying effort could blunt new competition to its products and reduce the savings anticipated in the federal health care overhaul.", "lead_paragraph": "In statehouses around the country, some of the nation\u2019s biggest biotechnology companies are lobbying intensively to limit generic competition to their blockbuster drugs, potentially cutting into the billions of dollars in savings on drug costs contemplated in the federal health care overhaul law.", "print_section": "A", "print_page": "1", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2013/01/29/business/29drug-sf/29drug-sf-articleLarge.jpg", "height": 400, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2013/01/29/business/29drug-sf/29drug-sf-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 400}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2013/01/29/business/29drug-sf/29drug-sf-jumbo.jpg", "height": 682, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2013/01/29/business/29drug-sf/29drug-sf-superJumbo.jpg", "height": 1365, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2013/01/29/business/29drug-sf/29drug-sf-thumbStandard-v2.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2013/01/29/business/29drug-sf/29drug-sf-thumbStandard-v2.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2013/01/29/business/29drug-sf/29drug-sf-thumbLarge-v2.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Biotech Firms,\r\nBillions at Risk,\r\nLobby States to\r\nLimit Generics", "kicker": null, "content_kicker": null, "print_headline": "Battle in States On Generic Copies Of Biotech Drugs", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "persons", "value": "Pollack, Andrew", "rank": 1, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 2, "major": "N"}, {"name": "subject", "value": "Biotechnology", "rank": 3, "major": "N"}, {"name": "subject", "value": "Law and Legislation", "rank": 4, "major": "N"}, {"name": "subject", "value": "Generic Brands and Products", "rank": 5, "major": "N"}, {"name": "subject", "value": "Inventions and Patents", "rank": 6, "major": "N"}, {"name": "organizations", "value": "Genentech Inc", "rank": 7, "major": "N"}, {"name": "organizations", "value": "AMGEN INC", "rank": 8, "major": "N"}, {"name": "subject", "value": "Patient Protection and Affordable Care Act (2010)", "rank": 9, "major": "N"}, {"name": "subject", "value": "States (US)", "rank": 10, "major": "N"}, {"name": "subject", "value": "Lobbying and Lobbyists", "rank": 11, "major": "N"}], "pub_date": "2013-01-29T02:24:42+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Andrew Pollack", "person": [{"firstname": "Andrew", "middlename": null, "lastname": "Pollack", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/1576bf66-b6ad-52a5-a273-4269277a2fa4", "word_count": 1237, "uri": "nyt://article/1576bf66-b6ad-52a5-a273-4269277a2fa4"}